MIDATECH PHARMA
R&D | Diabetes Vaccine

Twenty percent of the world's population suffer from an autoimmune disease which are difficult to treat and can severely impact the patients‘ health, quality of life, and life expectancy. Current autoimmune treatments are non-specific and suppress whole immune system which increases risk of infection and cancer. Midatech is developing a new approach to such treatments by targeting immune cells using a combination of GNP bound to disease causing antigens, that modulate the function of immune components such as T-cells from disease-causing to disease-regulating (tolerogenic response) without affecting the rest of the immune system. The current focus is the largest autoimmune disease of them all – type 1 diabetes.

In September 2016, with support from an EU programme grant, Midatech has commenced the first in human Phase I study of an innovative vaccine (MTX102) using its GNP technology in type 1 diabetes. The results from the study are expected in 2017

R&D
R&D
Diabetes Vaccine

Twenty percent of the world's population suffer from an autoimmune disease which are difficult to treat and can severely impact the patients‘ health, quality of life, and life expectancy. Current autoimmune treatments are non-specific and suppress whole immune system which increases risk of infection and cancer. Midatech is developing a new approach to such treatments by targeting immune cells using a combination of GNP bound to disease causing antigens, that modulate the function of immune components such as T-cells from disease-causing to disease-regulating (tolerogenic response) without affecting the rest of the immune system. The current focus is the largest autoimmune disease of them all – type 1 diabetes.

In September 2016, with support from an EU programme grant, Midatech has commenced the first in human Phase I study of an innovative vaccine (MTX102) using its GNP technology in type 1 diabetes. The results from the study are expected in 2017

© Copyright 2017 Midatech Pharma PLC